13:19:59 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-29 Kvartalsrapport 2024-Q3
2024-10-15 Halvårsutdelning ORNBV 0.81
2024-10-15 Halvårsutdelning ORNAV 0.81
2024-08-08 Kvartalsrapport 2024-Q2
2024-04-25 Kvartalsrapport 2024-Q1
2024-03-21 Halvårsutdelning ORNBV 0.81
2024-03-21 Halvårsutdelning ORNAV 0.81
2024-03-20 Årsstämma 2024
2024-02-13 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-17 Kvartalsrapport 2023-Q2
2023-04-27 Kvartalsrapport 2023-Q1
2023-03-23 Ordinarie utdelning ORNAV 1.60 EUR
2023-03-23 Ordinarie utdelning ORNBV 1.60 EUR
2023-03-22 Årsstämma 2023
2023-02-09 Bokslutskommuniké 2022
2022-10-20 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-03-24 Ordinarie utdelning ORNAV 1.50 EUR
2022-03-24 Ordinarie utdelning ORNBV 1.50 EUR
2022-03-23 Årsstämma 2022
2022-02-10 Bokslutskommuniké 2021
2021-10-20 Kvartalsrapport 2021-Q3
2021-07-19 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning ORNAV 1.50 EUR
2021-03-26 Ordinarie utdelning ORNBV 1.50 EUR
2021-03-25 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-10-21 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-07 Ordinarie utdelning ORNBV 1.50 EUR
2020-05-07 Ordinarie utdelning ORNAV 1.50 EUR
2020-05-06 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-03-26 Ordinarie utdelning ORNBV 1.50 EUR
2020-02-05 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-17 Kvartalsrapport 2019-Q2
2019-04-25 Kvartalsrapport 2019-Q1
2019-03-27 Ordinarie utdelning ORNAV 1.50 EUR
2019-03-27 Ordinarie utdelning ORNBV 1.50 EUR
2019-03-26 Årsstämma 2019
2019-02-06 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-07-18 Kvartalsrapport 2018-Q2
2018-04-24 Kvartalsrapport 2018-Q1
2018-03-21 Ordinarie utdelning ORNAV 1.45 EUR
2018-03-21 Ordinarie utdelning ORNBV 1.45 EUR
2018-03-20 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-07-19 Kvartalsrapport 2017-Q2
2017-05-18 Kapitalmarknadsdag 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-03-23 Ordinarie utdelning ORNAV 1.35 EUR
2017-03-23 Bonusutdelning ORNAV 0.2
2017-03-23 Bonusutdelning ORNBV 0.2
2017-03-23 Ordinarie utdelning ORNBV 1.35 EUR
2017-03-22 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-10-25 Kvartalsrapport 2016-Q3
2016-07-19 Kvartalsrapport 2016-Q2
2016-04-27 Kvartalsrapport 2016-Q1
2016-03-23 Ordinarie utdelning ORNBV 1.30 EUR
2016-03-23 Ordinarie utdelning ORNAV 1.30 EUR
2016-03-22 Årsstämma 2016
2016-02-02 Bokslutskommuniké 2015
2015-10-27 Kvartalsrapport 2015-Q3
2015-07-28 Kvartalsrapport 2015-Q2
2015-05-26 Kapitalmarknadsdag 2015
2015-04-29 Kvartalsrapport 2015-Q1
2015-03-25 Ordinarie utdelning ORNBV 1.30 EUR
2015-03-25 Ordinarie utdelning ORNAV 1.30 EUR
2015-03-24 Årsstämma 2015
2015-02-04 Bokslutskommuniké 2014
2014-10-21 Kvartalsrapport 2014-Q3
2014-07-29 Kvartalsrapport 2014-Q2
2014-04-29 Kvartalsrapport 2014-Q1
2014-03-26 Ordinarie utdelning ORNAV 1.25 EUR
2014-03-26 Ordinarie utdelning ORNBV 1.25 EUR
2014-03-25 Årsstämma 2014
2014-02-04 Bokslutskommuniké 2013
2013-10-22 Kvartalsrapport 2013-Q3
2013-07-30 Kvartalsrapport 2013-Q2
2013-04-23 Kvartalsrapport 2013-Q1
2013-03-20 Ordinarie utdelning ORNAV 1.30 EUR
2013-03-20 Ordinarie utdelning ORNBV 1.30 EUR
2013-03-19 Årsstämma 2013
2013-02-05 Bokslutskommuniké 2012
2012-10-23 Kvartalsrapport 2012-Q3
2012-07-31 Kvartalsrapport 2012-Q2
2012-05-24 Kapitalmarknadsdag 2012
2012-04-24 Kvartalsrapport 2012-Q1
2012-03-21 Ordinarie utdelning ORNAV 1.30 EUR
2012-03-21 Bonusutdelning ORNAV 0.12
2012-03-21 Ordinarie utdelning ORNBV 1.30 EUR
2012-03-21 Bonusutdelning ORNBV 0.12
2012-03-20 Årsstämma 2012
2012-02-07 Bokslutskommuniké 2011
2011-10-25 Kvartalsrapport 2011-Q3
2011-08-02 Kvartalsrapport 2011-Q2
2011-04-27 Kvartalsrapport 2011-Q1
2011-04-01 Bonusutdelning ORNBV 0.06
2011-04-01 Bonusutdelning ORNAV 0.06
2011-04-01 Ordinarie utdelning ORNAV 1.20 EUR
2011-04-01 Ordinarie utdelning ORNBV 1.20 EUR
2011-03-31 Årsstämma 2011
2011-02-09 Bokslutskommuniké 2010
2010-10-26 Kvartalsrapport 2010-Q3
2010-08-10 Kvartalsrapport 2010-Q2
2010-04-27 Kvartalsrapport 2010-Q1
2010-03-25 Ordinarie utdelning ORNBV 1.00 EUR
2010-03-25 Bonusutdelning ORNBV 0.1
2010-03-25 Bonusutdelning ORNAV 0.1
2010-03-25 Ordinarie utdelning ORNAV 1.00 EUR
2009-03-24 Ordinarie utdelning ORNAV 0.95 EUR
2009-03-24 Ordinarie utdelning ORNBV 0.95 EUR
2008-03-26 Ordinarie utdelning ORNBV 1.00 EUR
2007-04-03 Ordinarie utdelning ORNAV 1.00 EUR
2007-04-03 Ordinarie utdelning ORNBV 1.00 EUR
2006-03-22 Ordinarie utdelning ORNBV 0.85 EUR
2005-03-22 Ordinarie utdelning ORNAV 0.55 EUR
2005-03-22 Ordinarie utdelning ORNBV 0.55 EUR
2004-09-15 Bonusutdelning ORNAV 2.14
2004-09-15 Bonusutdelning ORNBV 2.14
2004-03-23 Ordinarie utdelning ORNAV 1.60 EUR
2004-03-23 Ordinarie utdelning ORNBV 1.60 EUR
2003-12-12 Bonusutdelning ORNAV 1.5
2003-12-12 Bonusutdelning ORNBV 1.5
2003-03-23 Ordinarie utdelning ORNAV 0.93 EUR
2003-03-23 Ordinarie utdelning ORNBV 0.93 EUR
2002-04-16 Ordinarie utdelning ORNBV 1.10 EUR
2002-04-16 Ordinarie utdelning ORNAV 1.10 EUR
2001-03-30 Ordinarie utdelning ORNAV 1.20 EUR
2001-03-30 Ordinarie utdelning ORNBV 1.20 EUR
2000-03-31 Ordinarie utdelning ORNAV 1.18 EUR
2000-03-31 Ordinarie utdelning ORNBV 1.18 EUR
1999-07-28 Bonusutdelning ORNBV 13.46
1999-07-28 Bonusutdelning ORNAV 13.46
1999-04-09 Ordinarie utdelning ORNAV 6.50 EUR
1999-04-09 Ordinarie utdelning ORNBV 6.50 EUR
1998-04-21 Ordinarie utdelning ORNBV 7.50 EUR
1998-04-21 Ordinarie utdelning ORNAV 7.50 EUR
1997-04-22 Ordinarie utdelning ORNAV 5.00 EUR
1997-04-22 Ordinarie utdelning ORNBV 5.00 EUR
1996-04-23 Ordinarie utdelning ORNBV 4.00 EUR
1996-04-23 Ordinarie utdelning ORNAV 4.00 EUR

Beskrivning

LandFinland
ListaLarge Cap Helsinki
SektorHälsovård
IndustriLäkemedel & Handel
Orion är en koncern med verksamhet inom läkemedelsindustrin. Bolaget bedriver forskning och utveckling av humana- och veterinära läkemedel, där störst fokus innehas inom sjukdomar som drabbar nervsystemet, samt onkologi och luftvägssjukdomar. Idag återfinns bolagets produkter på global nivå, med störst närvaro inom Norden och övriga Europa. Bolagets huvudkontor ligger i Esbo.
2020-06-04 13:30:00

        
ORION CORPORATION         PRESS RELEASE       4 JUNE 2020 at 2.30 p.m. EEST

 

Orion is developing an immuno-oncology (IO) drug discovery platform in the national research and innovation consortium Cancer IO

The national research and innovation project Cancer IO started in May as a part of Business Finland’s Personalized Health Program. The project will develop new solutions to enhance immunotherapy treatments and support the introduction of new therapies. Orion is one of the companies participating in the project, and the aim is to develop and establish an immuno-oncology drug discovery platform (IO platform) at Orion.

This project coordinated by the University of Helsinki will integrate a significant number of Finnish immuno-oncology projects, which will be carried out at the universities of Helsinki and Turku, three university hospitals and one central hospital as well as in eight Finnish companies. The Cancer IO project also includes several patient organisations and the nine largest IO-investing pharmaceutical companies. Orion is one of the pharmaceutical companies taking part in the project.

Oncology is one of Orion’s core therapy areas in pharmaceutical R&D. In the Cancer IO project, the aim is to develop and establish also an immuno-oncology drug discovery platform (IO platform) at Orion.

Cancer treatments are now increasingly combination treatments, in which immuno-oncology (IO) treatments are key components. IO treatments have shown their efficacy in cancer treatment and particularly when combined with other oncology treatments targeting the drives of tumour growth. The IO platform to be developed during the project will enable the development of new IO treatments in future.

“Collaboration with the academic and industry partners in the Cancer IO network will radically boost the achievement of these goals. The various participants will bring the right expertise and technologies into the project. The Cancer IO consortium will also give access to Finnish biobank samples and the unique cell models which provide opportunities for innovative solutions to the development of personalised therapies,” says Outi Vaarala, Orion’s new Senior Vice President, R&D as of 1 June 2020.

Since the research of IO treatments is a new area for Orion, the development of the research methods and technologies will require new kinds of competence and wide expertise. Orion already invested in strengthening this competence area last year and has recruited an IO team for the development of the IO platform.

Cancer IO
 

The Cancer IO programme seeks to meet the new challenges of the immuno-oncology era by supporting Finnish top-level research and innovation, by advancing the individualisation and introduction of cancer treatments in hospitals and by creating new methods to evaluate the efficacy of IO therapies in everyday use.

Immuno-oncology (IO)

Cancer immunotherapy or immuno-oncology (IO) is rapidly becoming the new foundation of cancer treatments in addition to traditional surgical and pharmaceutical treatments. However, immunotherapy is a completely different approach compared to all the therapies used so far. Instead of trying to directly destroy cancer cells, immunotherapy seeks unlock the body’s own immune system to fight cancer.

                                                                                                                                   
Contact person:
Outi Vaarala, Senior Vice President, R&D, Orion Corporation
Tel. +358 50 966 3472

Contact person for media:
Terhi Ormio, Vice President, Communications, Orion Corporation
Tel. +358 50 966 4646



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.